• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
  • ABOUT US
    • Presentation
    • People
    • Contact
  • Spanish
  • English

Commission authorises adapted COVID-19 vaccine for Member States’ autumn vaccination campaigns

Inicio » EU News » Health » Diseases » Commission authorises adapted COVID-19 vaccine for Member States’ autumn vaccination campaigns

4 de September de 2023

The Commission has authorised the Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech-Pfizer. This vaccine marks another important milestone in the fight against the disease. It is the third adaptation of this vaccine to respond to new COVID-19 variants.

covid vacuna

The vaccine is authorised for adults, children and infants above 6 months. In line with previous recommendations by EMA and the European Centre for Disease Prevention and Control (ECDC), adults and children from 5 years of age who require vaccination should have a single dose, irrespective of their COVID-19 vaccination history.

The authorisation comes after a stringent evaluation by the European Medicines Agency, under the accelerated assessment mechanism. The Commission authorised this adapted vaccine under an expedited procedure to allow Member States to prepare in time for their autumn-winter vaccination campaigns.

Researchers have identified antibodies that could defeat all coronaviruses

Background

With our EU Vaccines Strategy, the Commission continues to ensure that Member States have access to the latest authorised COVID-19 vaccines in quantities needed to protect the vulnerable parts of their population and deal with the epidemiological evolution of the virus.

In line with the ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants, BioNTech-Pfizer has adapted its COVID-19 vaccine to target the SARS-CoV-2 Omicron strain XBB.1.5. The adapted vaccine is also expected to increase the breadth of immunity against current dominant and emerging variants.

The amendment to the contract with BioNTech-Pfizer signed in May 2023 ensures that Member States continue to have access to vaccines adapted to new COVID-19 variants in the upcoming years.

More information: European Commission

Publicaciones relacionadas:

European Commission authorises second safe and effective vaccine against COVID-19 European Commission unveils EU vaccines strategy European Commission authorises first safe and effective vaccine against COVID-19 EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca SARS-CoV-2 mutations thwart body’s killer cells

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

European Commission authorises second safe and effective vaccine against COVID-19 European Commission unveils EU vaccines strategy European Commission authorises first safe and effective vaccine against COVID-19 EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca SARS-CoV-2 mutations thwart body’s killer cells

Footer

Logotipo en negativo del Centro de Documentación Europea de Almería
  • CDE Almería
  • Edificio Parque Científico-Tecnológico (Pita)
  • Planta: 1ª, Despacho: 2904120.
  • Ctra. Sacramento s/n. Almería (Spain)
  • Teléfono: (+34) 950 015266

HOME
NEWS
DOCUMENTATION
EUROPE ON THE NET
ABOUT US

  • LEGAL NOTICE
  • PRIVACY POLICY
  • COOKIE POLICY
  • ACCESSIBILITY
  • SITEMAP

Copyright © 2023 CDE Almería · Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

<p>El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. </p>

Politica de privacidad

El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. <a href="/politica-de-cookies" rel="noopener" target="_blank">Más información</a>

Cookies estrictamente necesarias

Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.

Básicamente la web no funcionara bien si no las activas.

Estas cookies son:

  • Comprobación de inicio de sesión.
  • Cookies de seguridad.
  • Aceptación/rechazo previo de cookies.

Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.

Cookies de terceros

Esta web utiliza Google Analytics, Google Tag Manager y Yandex Metrika para recopilar información anónima tal como el número de visitantes del sitio, o las páginas más populares.

Dejar estas cookies activas nos permite mejorar nuestra web.

¡Por favor, activa primero las cookies estrictamente necesarias para que podamos guardar tus preferencias!

Política de cookies

Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. Más información